More than 5 months after ditching efforts to open on public markets, California-based CardioDx is ready to take another swing at an initial public offering.

In regulatory documents filed this week the molecular diagnostics maker assigned new underwriters, named a couple of new executives and added 2 members to its board of directors. CardioDx has not yet revealed exact timing or terms for the revived IPO.

The company had previously filed for an $92 million IPO, with shares priced at $14-$16 apiece. CardioDx scuttled those plans mid-November, citing "unfavorable market conditions."

Renaissance Capital announced this week CardioDx’s renewed efforts at a Nasdaq showing, where the company will trade under the stock ticker CDX.

In parallel filings the company announced the appointments of Melinda Griffith as the new head of corporate development and general counsel and Doug Ross as the chief scientific officer. CardioDx also added James Tobin and Andrew Guggenhime to its board of directors.